000 02326 a2200625 4500
005 20250518015335.0
264 0 _c20190705
008 201907s 0 0 eng d
022 _a1741-7015
024 7 _a10.1186/s12916-018-1233-1
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGavilá, Joaquín
245 0 0 _aSafety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
_h[electronic resource]
260 _bBMC medicine
_c01 2019
300 _a8 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAntibodies, Monoclonal, Humanized
_xadministration & dosage
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xtherapeutic use
650 0 4 _aBreast Neoplasms
_xdrug therapy
650 0 4 _aCardiotoxicity
_xepidemiology
650 0 4 _aChemotherapy, Adjuvant
_xadverse effects
650 0 4 _aDoxorubicin
_xadministration & dosage
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMiddle Aged
650 0 4 _aNeoadjuvant Therapy
_xadverse effects
650 0 4 _aPaclitaxel
_xadministration & dosage
650 0 4 _aPolyethylene Glycols
_xadministration & dosage
650 0 4 _aReceptor, ErbB-2
650 0 4 _aTrastuzumab
_xadministration & dosage
700 1 _aOliveira, Mafalda
700 1 _aPascual, Tomás
700 1 _aPerez-Garcia, Jose
700 1 _aGonzàlez, Xavier
700 1 _aCanes, Jordi
700 1 _aParé, Laia
700 1 _aCalvo, Isabel
700 1 _aCiruelos, Eva
700 1 _aMuñoz, Montserrat
700 1 _aVirizuela, Juan A
700 1 _aRuiz, Isabel
700 1 _aAndrés, Raquel
700 1 _aPerelló, Antonia
700 1 _aMartínez, Jerónimo
700 1 _aMorales, Serafín
700 1 _aMarín-Aguilera, Mercedes
700 1 _aMartínez, Débora
700 1 _aQuero, Juan C
700 1 _aLlombart-Cussac, Antonio
700 1 _aPrat, Aleix
773 0 _tBMC medicine
_gvol. 17
_gno. 1
_gp. 8
856 4 0 _uhttps://doi.org/10.1186/s12916-018-1233-1
_zAvailable from publisher's website
999 _c29233156
_d29233156